2025 Q4 -tulosraportti
Vain PDF
23 päivää sitten
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 210 | - | - | ||
| 608 | - | - | ||
| 1 000 | - | - | ||
| 2 100 | - | - | ||
| 31 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·59 min sittenReceived this on VPS now. Known from a previous message, but relevant for everyone interested in the warrants. To the holders of warrants in Circio Holding ASA ISIN NO0013711523 (ticker: CRNAS) Dear Warrant holder, Circio Holding ASA (“Circio” or the “Company”) is pleased to provide practical information relating to the upcoming exercise of warrants. A total of 67,680,945 warrants (the “Warrants”) were issued on ISIN NO0013711523 in connection with the rights issue and related private placement (Nw.: frittstående tegningsretter), as announced in the stock exchange announcement published on 16 February 2026. Key terms and dates • Warrants outstanding: 67,680,945 • Warrant exercise terms: Each Warrant gives the holder the right to subscribe for one (1) new share in Circio at the exercise price. • Warrant trading: The Warrants are listed and tradable on the Oslo Stock Exchange under the ticker code “CRNAS” with ISIN NO0013711523. • Warrant trading period: The Warrants are tradable to and including 3 June 2026. • Warrant pricing period: 8–22 May 2026. • Warrant exercise price: 20% discount to the volume-weighted average trading price (VWAP) of the shares of Circio during the Warrant pricing period. • Announcement of exercise price: After market close on 22 May 2026 (Newsweb). • Warrant exercise period: 26 May – 9 June 2026. • Unexercised Warrants: Warrants not exercised by the end of the exercise period will lapse without any compensation to the holder. • Warrant payment date: On or about 12 June 2026. • Tradability and delivery of new shares: As soon as practicable after the Warrant payment date. Main alternatives for Warrant holders As a holder of Warrants, you have the following main alternatives: 1. 2. 3. 4. 5. Exercise currently held Warrants during the exercise period, pay the exercise price and receive new shares in Circio. Buy additional Warrants on the Oslo Stock Exchange. Subsequently exercise all held Warrants during the exercise period, pay the exercise price and receive new shares in Circio. Sell a portion of currently held Warrants during the trading period. Subsequently exercise the remaining Warrants held during the exercise period, pay the exercise price and receive new shares in Circio. Sell all currently held Warrants during the trading period on the Oslo Stock Exchange. Do nothing. Warrants not exercised by 9 June 2026 will lapse without any compensation to the holder. Information related to financing of Warrants With regard to the first three alternatives above (involving the exercise of Warrants), exercising Warrants means buying new shares in Circio at the exercise price (20% discount to VWAP as mentioned above), and the aggregate exercise price must be settled in cash on the Warrant payment date (on or about 12 June 2026). It is imperative that investors planning to exercise Warrants secure sufficient financing to cover the aggregate exercise price ahead of the Warrant payment date. Illustrative example: A holder of 100,000 Warrants (representing the right to buy 100,000 new shares in Circio at the exercise price) would need to pay the exercise price multiplied by the number of Warrants to exercise all Warrants. For example, at an exercise price of NOK 5, NOK 7.5 or NOK 10 per share, the holder would need NOK 500,000, NOK 750,000 or NOK 1,000,000, respectively, to exercise all Warrants. How to exercise Warrants During the exercise period, Warrants can be exercised (i) digitally through the websites of Pareto Securities and Circio, or (ii) manually by contacting Pareto Securities directly. More information about this will be announced after the exercise price has been set on 22 May 2026, ahead of the exercise period commencing on 26 May 2026. Further information about the Warrants The grant or purchase of Warrants by persons resident in, or who are citizens of, countries other than Norway or Sweden, may be affected by the laws of the relevant jurisdiction. For a further description of such restrictions, reference is made to Section 11 “Selling and Transfer Restrictions” in the securities note dated 13 January 2026 (the “Securities Note”, and together with a registration document dated 1 October 2025, and a registration document supplement and summary dated 13 January 2026, comprise the “Prospectus”). For more information about the Warrants, please refer to the Prospectus. The Prospectus is available on the Company’s website: https://www.circio.com/en/rightsissue2026/. Contact information Should you have any questions, please do not hesitate to contact us: Erik Digman Wiklund, CEO Phone: +47 413 33 536 Email: erik.wiklund@circio.com Lubor Gaal, CFO Phone: +34 683 34 3811 Email: lubor.gaal@circio.com
·3 t sittenA lot of euphoria and ecstasy in the forum here now. Have I missed something?
·3 t sitten · MuokattuCan recommend a Gran Reserva 2016 🤭 😂
·4 t sittenHISTORY REPEATS ITSELF – FOR THOSE WHO DARE. ♟️🧱 Most people fail to see the value of a breakthrough until it is already obvious. That's how the market works. First, they laugh. Then, they doubt. Then, they demand more proof. And when the evidence is finally clear enough for everyone, the price tag is completely different. That's exactly why early biotech is so difficult. You never get 100 % certainty at the bottom. You get data points. You get signals. You get external partners. You get in vitro. You get in vivo. You get ASGCT. You get dose-data. You get expression-data. You get signs that the technology is moving through the industrial filters. And then you have to take a stand before everything is fully proven. It's not for everyone. Biotech requires nerves. It requires risk understanding. And one should never invest more than one can afford to lose. But one should also not expect asymmetric upside by waiting until the whole world agrees. Today, some call Circio hype. Fair. But we have read the data. We have seen 60x expression in the eye. 40x in the heart. 22x higher output at 10x lower dose. We see AAV. LNP. Acuitas. TraffikGene. Partner-funded in vivo testing. ASGCT Boston. This is not a fully proven case. But it's not just an idea anymore either. The stage is set. Boston waits. We know what we own. ♟️🧱🍷
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
23 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·59 min sittenReceived this on VPS now. Known from a previous message, but relevant for everyone interested in the warrants. To the holders of warrants in Circio Holding ASA ISIN NO0013711523 (ticker: CRNAS) Dear Warrant holder, Circio Holding ASA (“Circio” or the “Company”) is pleased to provide practical information relating to the upcoming exercise of warrants. A total of 67,680,945 warrants (the “Warrants”) were issued on ISIN NO0013711523 in connection with the rights issue and related private placement (Nw.: frittstående tegningsretter), as announced in the stock exchange announcement published on 16 February 2026. Key terms and dates • Warrants outstanding: 67,680,945 • Warrant exercise terms: Each Warrant gives the holder the right to subscribe for one (1) new share in Circio at the exercise price. • Warrant trading: The Warrants are listed and tradable on the Oslo Stock Exchange under the ticker code “CRNAS” with ISIN NO0013711523. • Warrant trading period: The Warrants are tradable to and including 3 June 2026. • Warrant pricing period: 8–22 May 2026. • Warrant exercise price: 20% discount to the volume-weighted average trading price (VWAP) of the shares of Circio during the Warrant pricing period. • Announcement of exercise price: After market close on 22 May 2026 (Newsweb). • Warrant exercise period: 26 May – 9 June 2026. • Unexercised Warrants: Warrants not exercised by the end of the exercise period will lapse without any compensation to the holder. • Warrant payment date: On or about 12 June 2026. • Tradability and delivery of new shares: As soon as practicable after the Warrant payment date. Main alternatives for Warrant holders As a holder of Warrants, you have the following main alternatives: 1. 2. 3. 4. 5. Exercise currently held Warrants during the exercise period, pay the exercise price and receive new shares in Circio. Buy additional Warrants on the Oslo Stock Exchange. Subsequently exercise all held Warrants during the exercise period, pay the exercise price and receive new shares in Circio. Sell a portion of currently held Warrants during the trading period. Subsequently exercise the remaining Warrants held during the exercise period, pay the exercise price and receive new shares in Circio. Sell all currently held Warrants during the trading period on the Oslo Stock Exchange. Do nothing. Warrants not exercised by 9 June 2026 will lapse without any compensation to the holder. Information related to financing of Warrants With regard to the first three alternatives above (involving the exercise of Warrants), exercising Warrants means buying new shares in Circio at the exercise price (20% discount to VWAP as mentioned above), and the aggregate exercise price must be settled in cash on the Warrant payment date (on or about 12 June 2026). It is imperative that investors planning to exercise Warrants secure sufficient financing to cover the aggregate exercise price ahead of the Warrant payment date. Illustrative example: A holder of 100,000 Warrants (representing the right to buy 100,000 new shares in Circio at the exercise price) would need to pay the exercise price multiplied by the number of Warrants to exercise all Warrants. For example, at an exercise price of NOK 5, NOK 7.5 or NOK 10 per share, the holder would need NOK 500,000, NOK 750,000 or NOK 1,000,000, respectively, to exercise all Warrants. How to exercise Warrants During the exercise period, Warrants can be exercised (i) digitally through the websites of Pareto Securities and Circio, or (ii) manually by contacting Pareto Securities directly. More information about this will be announced after the exercise price has been set on 22 May 2026, ahead of the exercise period commencing on 26 May 2026. Further information about the Warrants The grant or purchase of Warrants by persons resident in, or who are citizens of, countries other than Norway or Sweden, may be affected by the laws of the relevant jurisdiction. For a further description of such restrictions, reference is made to Section 11 “Selling and Transfer Restrictions” in the securities note dated 13 January 2026 (the “Securities Note”, and together with a registration document dated 1 October 2025, and a registration document supplement and summary dated 13 January 2026, comprise the “Prospectus”). For more information about the Warrants, please refer to the Prospectus. The Prospectus is available on the Company’s website: https://www.circio.com/en/rightsissue2026/. Contact information Should you have any questions, please do not hesitate to contact us: Erik Digman Wiklund, CEO Phone: +47 413 33 536 Email: erik.wiklund@circio.com Lubor Gaal, CFO Phone: +34 683 34 3811 Email: lubor.gaal@circio.com
- ·3 t sittenA lot of euphoria and ecstasy in the forum here now. Have I missed something?
- ·3 t sitten · MuokattuCan recommend a Gran Reserva 2016 🤭 😂
- ·4 t sittenHISTORY REPEATS ITSELF – FOR THOSE WHO DARE. ♟️🧱 Most people fail to see the value of a breakthrough until it is already obvious. That's how the market works. First, they laugh. Then, they doubt. Then, they demand more proof. And when the evidence is finally clear enough for everyone, the price tag is completely different. That's exactly why early biotech is so difficult. You never get 100 % certainty at the bottom. You get data points. You get signals. You get external partners. You get in vitro. You get in vivo. You get ASGCT. You get dose-data. You get expression-data. You get signs that the technology is moving through the industrial filters. And then you have to take a stand before everything is fully proven. It's not for everyone. Biotech requires nerves. It requires risk understanding. And one should never invest more than one can afford to lose. But one should also not expect asymmetric upside by waiting until the whole world agrees. Today, some call Circio hype. Fair. But we have read the data. We have seen 60x expression in the eye. 40x in the heart. 22x higher output at 10x lower dose. We see AAV. LNP. Acuitas. TraffikGene. Partner-funded in vivo testing. ASGCT Boston. This is not a fully proven case. But it's not just an idea anymore either. The stage is set. Boston waits. We know what we own. ♟️🧱🍷
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 210 | - | - | ||
| 608 | - | - | ||
| 1 000 | - | - | ||
| 2 100 | - | - | ||
| 31 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
23 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·59 min sittenReceived this on VPS now. Known from a previous message, but relevant for everyone interested in the warrants. To the holders of warrants in Circio Holding ASA ISIN NO0013711523 (ticker: CRNAS) Dear Warrant holder, Circio Holding ASA (“Circio” or the “Company”) is pleased to provide practical information relating to the upcoming exercise of warrants. A total of 67,680,945 warrants (the “Warrants”) were issued on ISIN NO0013711523 in connection with the rights issue and related private placement (Nw.: frittstående tegningsretter), as announced in the stock exchange announcement published on 16 February 2026. Key terms and dates • Warrants outstanding: 67,680,945 • Warrant exercise terms: Each Warrant gives the holder the right to subscribe for one (1) new share in Circio at the exercise price. • Warrant trading: The Warrants are listed and tradable on the Oslo Stock Exchange under the ticker code “CRNAS” with ISIN NO0013711523. • Warrant trading period: The Warrants are tradable to and including 3 June 2026. • Warrant pricing period: 8–22 May 2026. • Warrant exercise price: 20% discount to the volume-weighted average trading price (VWAP) of the shares of Circio during the Warrant pricing period. • Announcement of exercise price: After market close on 22 May 2026 (Newsweb). • Warrant exercise period: 26 May – 9 June 2026. • Unexercised Warrants: Warrants not exercised by the end of the exercise period will lapse without any compensation to the holder. • Warrant payment date: On or about 12 June 2026. • Tradability and delivery of new shares: As soon as practicable after the Warrant payment date. Main alternatives for Warrant holders As a holder of Warrants, you have the following main alternatives: 1. 2. 3. 4. 5. Exercise currently held Warrants during the exercise period, pay the exercise price and receive new shares in Circio. Buy additional Warrants on the Oslo Stock Exchange. Subsequently exercise all held Warrants during the exercise period, pay the exercise price and receive new shares in Circio. Sell a portion of currently held Warrants during the trading period. Subsequently exercise the remaining Warrants held during the exercise period, pay the exercise price and receive new shares in Circio. Sell all currently held Warrants during the trading period on the Oslo Stock Exchange. Do nothing. Warrants not exercised by 9 June 2026 will lapse without any compensation to the holder. Information related to financing of Warrants With regard to the first three alternatives above (involving the exercise of Warrants), exercising Warrants means buying new shares in Circio at the exercise price (20% discount to VWAP as mentioned above), and the aggregate exercise price must be settled in cash on the Warrant payment date (on or about 12 June 2026). It is imperative that investors planning to exercise Warrants secure sufficient financing to cover the aggregate exercise price ahead of the Warrant payment date. Illustrative example: A holder of 100,000 Warrants (representing the right to buy 100,000 new shares in Circio at the exercise price) would need to pay the exercise price multiplied by the number of Warrants to exercise all Warrants. For example, at an exercise price of NOK 5, NOK 7.5 or NOK 10 per share, the holder would need NOK 500,000, NOK 750,000 or NOK 1,000,000, respectively, to exercise all Warrants. How to exercise Warrants During the exercise period, Warrants can be exercised (i) digitally through the websites of Pareto Securities and Circio, or (ii) manually by contacting Pareto Securities directly. More information about this will be announced after the exercise price has been set on 22 May 2026, ahead of the exercise period commencing on 26 May 2026. Further information about the Warrants The grant or purchase of Warrants by persons resident in, or who are citizens of, countries other than Norway or Sweden, may be affected by the laws of the relevant jurisdiction. For a further description of such restrictions, reference is made to Section 11 “Selling and Transfer Restrictions” in the securities note dated 13 January 2026 (the “Securities Note”, and together with a registration document dated 1 October 2025, and a registration document supplement and summary dated 13 January 2026, comprise the “Prospectus”). For more information about the Warrants, please refer to the Prospectus. The Prospectus is available on the Company’s website: https://www.circio.com/en/rightsissue2026/. Contact information Should you have any questions, please do not hesitate to contact us: Erik Digman Wiklund, CEO Phone: +47 413 33 536 Email: erik.wiklund@circio.com Lubor Gaal, CFO Phone: +34 683 34 3811 Email: lubor.gaal@circio.com
- ·3 t sittenA lot of euphoria and ecstasy in the forum here now. Have I missed something?
- ·3 t sitten · MuokattuCan recommend a Gran Reserva 2016 🤭 😂
- ·4 t sittenHISTORY REPEATS ITSELF – FOR THOSE WHO DARE. ♟️🧱 Most people fail to see the value of a breakthrough until it is already obvious. That's how the market works. First, they laugh. Then, they doubt. Then, they demand more proof. And when the evidence is finally clear enough for everyone, the price tag is completely different. That's exactly why early biotech is so difficult. You never get 100 % certainty at the bottom. You get data points. You get signals. You get external partners. You get in vitro. You get in vivo. You get ASGCT. You get dose-data. You get expression-data. You get signs that the technology is moving through the industrial filters. And then you have to take a stand before everything is fully proven. It's not for everyone. Biotech requires nerves. It requires risk understanding. And one should never invest more than one can afford to lose. But one should also not expect asymmetric upside by waiting until the whole world agrees. Today, some call Circio hype. Fair. But we have read the data. We have seen 60x expression in the eye. 40x in the heart. 22x higher output at 10x lower dose. We see AAV. LNP. Acuitas. TraffikGene. Partner-funded in vivo testing. ASGCT Boston. This is not a fully proven case. But it's not just an idea anymore either. The stage is set. Boston waits. We know what we own. ♟️🧱🍷
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 210 | - | - | ||
| 608 | - | - | ||
| 1 000 | - | - | ||
| 2 100 | - | - | ||
| 31 | - | - |
Välittäjätilasto
Dataa ei löytynyt